摘要
目的分析紫杉醇白蛋白结合型与多西他赛联合奈达铂一线治疗晚期食管癌临床治疗效果。方法方便选取2018年6月—2021年6月在盐城市第一人民医院肿瘤科就诊的43例晚期既往未行过化疗治疗的食管癌患者为研究对象,随机分为两组,研究组共入组21例,采用紫杉醇白蛋白结合型联合奈达铂方案化疗,对照组共入组22例,采用多西他赛联合奈达铂方案化疗。所有患者经两个周期治疗后采用影像学评估治疗效果。结果治疗后,两组症状缓解情况比较,差异无统计学意义(P>0.05)。研究组ORR为76.19%,DCR为95.23%,中位PFS为10.5个月。对照组ORR为59.09%,DCR为86.36%,中位PFS为7.87个月。研究组的ORR、DCR高于对照组,但差异无统计学意义(P>0.05);两组中位无疾病进展期(mPFS)比较,差异有统计学意义(Z=-2.102,P=0.036)。研究组中出现周围神经毒性的病例数明显高于对照组,差异有统计学意义(Z=-2.379,P=0.017)。两组患者经过化疗后体力状况评分比较,差异有统计学意义(Z=-2.018,P=0.044)。结论紫杉醇白蛋白结合型较传统多西他赛对于晚期食管癌一线使用可以改善患者症状、减少不良反应,还可以延长无疾病生存期,为晚期食管癌一线治疗较好选择之一。
Objective To analyze the clinical efficacy of paclitaxel albumin-binding type and docetaxel combined with nedaplatin in first-line treatment of advanced esophageal cancer.Methods From June 2018 to June 2021,43 patients with advanced esophageal cancer who had not received chemotherapy treatment in the oncology department of the First People's Hospital of Yancheng City were conveniently selected as the study objects,and were randomly divided into two groups.The study group included 21 patients,who were treated with paclitaxel albumin combined with Nedaplatin,and the control group included 22 patients,who were treated with docetaxel combined with Nedaplatin.After two cycles of treatment,all patients were evaluated for treatment effectiveness using imaging.Results After treatment,there was no statistically significant difference in symptom relief between the two groups(P>0.05).The ORR of the study group was 76.19%,the DCR was 95.23%,and the median PFS was 10.5 months.The control group had an ORR of 59.09%,a DCR of 86.36%,and a median PFS of 7.87 months.The ORR and DCR of the study group were higher than those of the control group,but the difference was not statistically significant(P>0.05).There was a statistically significant difference in the median progression free period(mPFS)between the two groups(Z=-2.102,P=0.036).The number of cases of peripheral neurotoxicity in the study group was significantly higher than that in the control group,the difference was statistically significant(Z=-2.379,P=0.017).The difference in physical condition scores between the two groups of patients after chemotherapy was statistically significant(Z=-2.018,P=0.044).Conclusion Compared to traditional docetaxel,paclitaxel albumin binding therapy can improve patient symptoms,reduce adverse reactions,and prolong disease-free survival in advanced esophageal cancer,making it one of the better first-line treatments for advanced esophageal cancer.
作者
衣素琴
刘红旗
严文跃
YI Suqin;LIU Hongqi;YAN Wenyue(Department of Oncology,Yancheng First People's Hospital,Yancheng,Jiangsu Province,224001 China)
出处
《中外医疗》
2023年第16期5-8,13,共5页
China & Foreign Medical Treatment
关键词
紫杉醇白蛋白结合型
多西他赛
奈达铂
食管癌
Paclitaxel albumin-binding type
Docetaxel
Nedaplatin
Carcinoma of esophagus
